fda approves first oral glp-1 obesity drug august 21 2025 for weight management FDA Approves First ORAL GLP-1

Topics:

The medication, sold by Eli Lilly and Company under the name Mounjaro, will be available in six different doses and come in an auto-injector pen

[DOI] [PMC free article] [PubMed] [Google Scholar] 21.Di Loreto C., Minarelli V., Nasini G., Norgiolini R., Del Sindaco P

Diagnosis typically involves a combination of clinical assessment, laboratory tests, and imaging studies (ultrasound abdomen, magnetic resonance elastography) with liver biopsy remaining the gold standard for staging of hepatitis and hepatic fibrosis

Clinical Trial Evidence: Landmark cardiovascular outcome trials (CVOTs) like the SELECT trial (for semaglutide) have shown a significant reduction in major adverse cardiovascular events (MACE), including heart attack, stroke, and cardiovascular death

After stratification by specific GLP-1 receptor agonist-SGLT-2 inhibitor combinations, the hazard ratios ranged from 0.64 for the liraglutide-dapagliflozin combination to 1.18 for the liraglutide-empagliflozin combination with confidence intervals overlapping each other (supplementary table E)